NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) on Monday released topline data from pre-specified Alzheimers Disease biomarker analyses in the Phase 3 BROADWAY clinical trial. The study was primaril… [+2509 chars]...
Read moreNewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is one of the 13 Biotech Stocks with Huge Upside Potential. It is now under Stifels coverage, with a buy rating and a $44 price target. NewAmsterdam Ph… [+1702 chars]...
Read moreSome people cant get their bad cholesterol levels down, even if they take cholesterol-lowering meds. A new clinical trial using a combination of existing and not-yet-released cholesterol tablets lowe… [+2445 chars]...
Read moreNewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) is one of 1,077 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare NewAmsterdam … [+3962 chars]...
Read moreNewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) is one of 1,075 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare New… [+3986 chars]...
Read moreNewAmsterdam Pharma (NASDAQ:NAMS – Free Report) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for NewAmsterdam Pharma in a report released on Monda… [+5129 chars]...
Read more